Zacks Investment Research upgraded shares of aTyr Pharma, Inc. (NASDAQ:LIFE) from a hold rating to a buy rating in a report issued on Wednesday, July 12th. Zacks Investment Research currently has $3.75 target price on the biotechnology company’s stock.

According to Zacks, “aTyr Pharma, Inc. is a bio-therapeutics company. The Company is involved in the discovery and development of medicines for severe, rare diseases of physiological modulators. aTyr Pharma, Inc. is a based in SAN DIEGO, United States. “

LIFE has been the topic of a number of other research reports. BMO Capital Markets reaffirmed a hold rating on shares of aTyr Pharma in a report on Wednesday, May 24th. Citigroup Inc. upped their price objective on aTyr Pharma from $3.00 to $4.00 and gave the stock a neutral rating in a report on Monday, March 20th. J P Morgan Chase & Co reissued a hold rating on shares of aTyr Pharma in a report on Saturday, March 18th. Finally, ValuEngine raised aTyr Pharma from a sell rating to a hold rating in a report on Saturday, July 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and one has issued a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $3.65.

Shares of aTyr Pharma (LIFE) opened at 3.15 on Wednesday. The company has a 50-day moving average of $3.45 and a 200-day moving average of $3.37. The firm’s market cap is $74.99 million. aTyr Pharma has a 1-year low of $2.10 and a 1-year high of $4.45.

aTyr Pharma (NASDAQ:LIFE) last announced its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.56) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.50) by $0.06. Analysts predict that aTyr Pharma will post ($2.18) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “aTyr Pharma, Inc. (LIFE) Raised to “Buy” at Zacks Investment Research” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/08/08/atyr-pharma-inc-life-upgraded-to-buy-at-zacks-investment-research-updated-updated-updated.html.

An institutional investor recently raised its position in aTyr Pharma stock. EcoR1 Capital LLC increased its position in shares of aTyr Pharma, Inc. (NASDAQ:LIFE) by 134.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,292,659 shares of the biotechnology company’s stock after buying an additional 1,315,673 shares during the period. aTyr Pharma accounts for about 2.0% of EcoR1 Capital LLC’s holdings, making the stock its 13th largest position. EcoR1 Capital LLC owned about 9.65% of aTyr Pharma worth $8,024,000 as of its most recent SEC filing. Institutional investors and hedge funds own 47.03% of the company’s stock.

aTyr Pharma Company Profile

aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.

Get a free copy of the Zacks research report on aTyr Pharma (LIFE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for aTyr Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma Inc. and related stocks with our FREE daily email newsletter.